On March 11, 2026, under the guidance of the China Council for the Promotion of International Trade (CCPIT) of Guangzhou Development District and Huangpu District, the "Guangdong-Jiangsu Collaborative Innovation, Smart Pharma Sails Far – Biomedical Industry-Talent Integration Exchange Meeting" was successfully held at Suzhou Ascentage Pharma. The event was co-organized by the Guangzhou Development District Biomedical & Health Industry Promotion Association and the Zhongshan University Suzhou Alumni Association, and co-hosted by Canton Biologics and Suzhou Ascentage Pharma.

1. Canton Biologics Co-Hosts, Building a Bridge for Industry Exchange Between Guangdong and Jiangsu

The event took "industry as a bridge and talent as a lifeline," deeply linking the core biomedical resources of the Guangdong-Hong Kong-Macao Greater Bay Area and the Yangtze River Delta. As an outstanding representative of biomedical enterprises in Guangzhou Development District, Canton Biologics co-hosted the event together with Suzhou Ascentage Pharma, actively promoting industry exchange, technology transfer, and talent collaboration between the two regions.

2. Government and Enterprises Gather, Discussing New Opportunities for Synergistic Development

Attending leaders unanimously agreed that Guangzhou and Suzhou, as core cities in China's biomedical industry, boast solid industrial foundations, abundant innovation vitality, and significant complementary advantages. With biomedicine as the link and university alumni resources as the bridge, the event successfully built a practical platform for industry exchange, technology transfer, and talent collaboration between the Greater Bay Area and the Yangtze River Delta – a vivid example of synergistic development in the biomedical field across the two regions.

3. Canton Biologics Shares Hands-On CMC Development Experience

Dr. Han Yue, Vice President of Canton Biologics, delivered a keynote speech titled "CMC Development Challenges and Solutions for Bispecific Antibodies and Complex Recombinant Proteins." Dr. Han provided an in-depth analysis of key CMC difficulties in the R&D and manufacturing of bispecific antibodies and complex recombinant proteins, including low expression levels, aggregate formation, and uneven glycosylation modifications. Drawing on Canton Biologics' years of hands-on experience, she offered systematic solutions. She pointed out that as complex molecules such as bispecific antibodies enter late-stage clinical trials and commercial phases, establishing a robust CMC development strategy is crucial.

4. Building a Regular Bridge, Guangdong-Jiangsu Collaboration Sets Sail Again

This event served as an important platform for Guangzhou Development District and Huangpu District to link with the Yangtze River Delta and deepen the integration of industry and talent in biomedicine. As a key member of the biomedical enterprise community in Guangzhou Development District, Canton Biologics is committed to providing high-quality CDMO services to biopharmaceutical companies worldwide.

Looking ahead, Canton Biologics will continue to leverage its technological advantages, rely on the sound industrial ecosystem and policy support of Guangzhou Development District, and actively connect with biomedical resources in the Yangtze River Delta. It aims to build a regular platform for industry exchange, technology transfer, and talent collaboration between Guangdong and Jiangsu, facilitating a two-way synergy and win-win development between the Greater Bay Area and the Yangtze River Delta biomedical industries, and contributing its strength to the innovation and upgrading of China's biomedical industry.